Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Archives

You are currently viewing the 2008 archives
Click here to return to the current data set

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: ganciclovir

« Back to Dashboard

Summary for Generic Name: ganciclovir

Tradenames:5
Patents:1
Applicants:4
NDAs:5
Drug Master File Entries: see list21
Suppliers: see list1
Therapeutic Class:Antivirals

Clinical Trials for: ganciclovir

Topical Administration of 0.15% Ganciclovir Gel for CMV Anterior Uveitis / Endotheliitis
Status: Recruiting Condition: Cytomegalovirus Anterior Segment Infection; Anterior Uveitis; Endotheliitis

Study of Ganciclovir/Valganciclovir for Prevention of Cytomegalovirus Reactivation in Acute Injury of the Lung and Respiratory Failure
Status: Recruiting Condition: Acute Lung Injury; Acute Respiratory Distress Syndrome; Respiratory Failure

Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
Status: Terminated Condition: Allogeneic Stem Cell Transplantation

Individualization of Ganciclovir and Valganciclovir Doses Using Bayesian Prediction in Renal Transplant Patients.
Status: Recruiting Condition: Infection in Solid Organ Transplant Recipients

Evaluate the Use of Ganciclovir Gel 0.3% for the Treatment of Conjunctivitis Caused by Adenovirus
Status: Not yet recruiting Condition: Conjunctivitis; Adenovirus.

Ganciclovir 0,15% Ophthalmic Gel in the Treatment of Adenovirus Keratoconjuntivitis
Status: Completed Condition: Conjunctivitis, Viral; Adenoviridae Infections

Valganciclovir for Treatment of Cytomegalovirus Infection in Solid Organ Transplant Patients
Status: Completed Condition: Cytomegalovirus Infection

Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant
Status: Terminated Condition: Cytomegalovirus Infections

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma
Status: Terminated Condition: Lymphoma; Lymphoproliferative Disorder

Valganciclovir in Congenital CMV Infants
Status: Completed Condition: Cytomegalovirus Infections

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Exclusivity Expiration
Ranbaxy
GANCICLOVIR
ganciclovir
CAPSULE; ORAL076457Jun 27, 2003RXYes<disabled><disabled>
Ranbaxy
GANCICLOVIR
ganciclovir
CAPSULE; ORAL076457Jun 27, 2003RXNo<disabled><disabled>
Roche Palo
CYTOVENE
ganciclovir
CAPSULE; ORAL020460Dec 22, 1994DISCNNo<disabled><disabled>
Roche Palo
CYTOVENE IV
ganciclovir sodium
INJECTABLE; INJECTION019661Jun 23, 1989RXYes<disabled><disabled>
Bausch And Lomb
VITRASERT
ganciclovir
IMPLANT; IMPLANTATION020569Mar 4, 1996RXYes5,378,475<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc